Back to Newsroom

Catalyst Pharma’s lead drug succeeds in late-stage study

Sept 29 (Reuters) – Catalyst Pharmaceutical Partners Inc said its lead drug was found superior in treating symptoms associated with a rare autoimmune disorder, compared with a placebo.

The company’s shares rose about 22 percent in extended trading on Monday.

The late-stage trial tested the drug, Firdapse, in 38 patients with Lambert-Eaton Myasthenic Syndrome, the company said.

Named after two neurologists at a Minnesota-based Mayo Clinic – Edward Lambert and Lee Eaton – the neuromuscular disease causes progressive muscle weakness, and is often associated with cancer.

Click here to read the full article